최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0493829 (2017-04-21) |
등록번호 | US-10064959 (2018-09-04) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 381 |
The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.
1. A synthetic messenger ribonucleic acid (mRNA) that is synthesized according to a method comprising the steps of: a) providing a complementary deoxyribonucleic acid (cDNA) that encodes a pharmaceutical protein of interest;b) selecting a nucleotide that disrupts a binding of a major groove binding
1. A synthetic messenger ribonucleic acid (mRNA) that is synthesized according to a method comprising the steps of: a) providing a complementary deoxyribonucleic acid (cDNA) that encodes a pharmaceutical protein of interest;b) selecting a nucleotide that disrupts a binding of a major groove binding partner with the mRNA, wherein the nucleotide has decreased binding affinity to the major groove binding partner selected from the group consisting of toll-like receptor (TLR) 3, TLR7, TLR8, retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and wherein the nucleotide comprises a modification on the major groove face of the nucleobase where an atom of the major groove face of the nucleobase is replaced or substituted with an alkyl group; andc) contacting the provided cDNA and the selected nucleotide with an RNA polymerase under conditions such that an mRNA transcript is synthesized. 2. The synthetic mRNA of claim 1, wherein the method further comprises after c), the step of: d) 5′-capping the mRNA transcript concomitantly or post-transcriptionally such that the mRNA is synthesized. 3. The synthetic mRNA of claim 1, wherein the mRNA is at least 300 nucleotides in length. 4. The synthetic mRNA of claim 1, wherein the nucleotide comprises a modification on the major groove face of a pyrimidine nucleobase. 5. The synthetic mRNA of claim 4, wherein the pyrimidine nucleobase is selected from cytosine and uracil. 6. The synthetic mRNA of claim 5, wherein the pyrimidine nucleobase is uracil. 7. The synthetic mRNA of claim 5, wherein the pyrimidine nucleobase is cytosine. 8. The synthetic mRNA of claim 5, wherein the nucleotide comprises 1-methyl-pseudouridine or 5-methyl-uridine. 9. The synthetic mRNA of claim 8, wherein the nucleotide comprises 1-methyl-pseudouridine. 10. The synthetic mRNA of claim 7, wherein the nucleotide comprises 5-methyl-cytidine. 11. The synthetic mRNA of claim 4, wherein the major groove binding partner is TLR3, TLR7, or TLR8. 12. The synthetic mRNA of claim 4, wherein the major groove binding partner is RIG-I, MDA5, or LGP2. 13. A pharmaceutical composition comprising the synthetic mRNA of claim 1 and a pharmaceutically acceptable carrier. 14. A pharmaceutical composition comprising the synthetic mRNA of claim 3 and a pharmaceutically acceptable carrier. 15. A pharmaceutical composition comprising the synthetic mRNA of claim 4 and a pharmaceutically acceptable carrier. 16. A pharmaceutical composition comprising the synthetic mRNA of claim 6 and a pharmaceutically acceptable carrier. 17. A pharmaceutical composition comprising the synthetic mRNA of claim 7 and a pharmaceutically acceptable carrier. 18. A pharmaceutical composition comprising the synthetic mRNA of claim 8 and a pharmaceutically acceptable carrier. 19. A pharmaceutical composition comprising the synthetic mRNA of claim 9 and a pharmaceutically acceptable carrier. 20. A pharmaceutical composition comprising the synthetic mRNA of claim 10 and a pharmaceutically acceptable carrier. 21. The synthetic mRNA of claim 2, wherein the 5′-capping is performed concomitantly. 22. The synthetic mRNA of claim 2, wherein the mRNA is at least 300 nucleotides in length. 23. The synthetic mRNA of claim 2, wherein the nucleotide comprises a modification on the major groove face of a pyrimidine nucleobase. 24. The synthetic mRNA of claim 23, wherein the pyrimidine nucleobase is selected from cytosine and uracil. 25. The synthetic mRNA of claim 24, wherein the nucleotide comprises 1-methyl-pseudouridine or 5-methyl-uridine. 26. The synthetic mRNA of claim 23, wherein the major groove binding partner is TLR3, TLR7, or TLR8. 27. The synthetic mRNA of claim 23, wherein the major groove binding partner is RIG-I, MDA5, or LGP2. 28. A pharmaceutical composition comprising the synthetic mRNA of claim 2 and a pharmaceutically acceptable carrier. 29. A pharmaceutical composition comprising the synthetic mRNA of claim 22 and a pharmaceutically acceptable carrier. 30. A pharmaceutical composition comprising the synthetic mRNA of claim 23 and a pharmaceutically acceptable carrier.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.